Threat to community

The lack of novel antibiotics in the development pipeline of the pharmaceutical industry will not be eliminated overnight as can be judged from the required development time lines: The sequence from identification of an initial hit compound, subsequent lead optimization and characterization, preclinical and the various phases of clinical development up to submission for marketing approval by the regulatory authorities, can last anywhere from 6-10 years. With the current widespread use of antibiotics, epidemiologists predict a steadily increasing number of MDR bacteria for which – in the absence of novel antibiotics - there will be no effective treatments.